<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00674791</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00000902</org_study_id>
    <nct_id>NCT00674791</nct_id>
  </id_info>
  <brief_title>Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease</brief_title>
  <official_title>A Phase I Study of Cancer Peptides Plus GM-CSF and Adjuvant (Montanide ISA 51) Following Completion of Prescribed Chemotherapy or Trastuzumab for TXN2-3M0 or Metastatic Breast Cancer With No Evidence of Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immunotope</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and feasibility of administering a peptide vaccine&#xD;
      consisting of twelve different tumor-rejection antigens to patients with high risk (TxN2-3M0)&#xD;
      or metastatic breast cancer with no evidence of disease following their completion of&#xD;
      systemic therapy. The vaccine is designed to elicit immune responses against twelve different&#xD;
      pathways that are essential to tumor growth, survival and metastasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary endpoint will be to determine the safety and feasibility of administering cancer&#xD;
      peptides to patients with high risk (TxN2-3M0) or metastatic breast cancer with no evidence&#xD;
      of disease following their completion of systemic therapy, with the secondary objectives of&#xD;
      evaluating immune response disease relapse survival. Two cohorts of 9 patients each will be&#xD;
      treated with different doses of the vaccine. They will receive the peptide vaccine&#xD;
      subcutaneously on weeks 0,1,2,4,5, and 6 and then receive the immunizations every 1 month for&#xD;
      6 months or disease recurrence. Toxicity will be assessed at each dose level using CTCv3&#xD;
      toxicity criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety/tolerability: Number of subjects with dose limiting toxicity after 3 immunizations.</measure>
    <time_frame>Status post-3 immunizations</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunologic response: Number of subjects with tumor antigen specific immune response after 3 immunizations.</measure>
    <time_frame>Status post-3 immunizations</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">13</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>OCPM Immunotherapeutic Vaccine</intervention_name>
    <description>Patients will receive 1 injection into each thigh at each of 6 visits: week 0, week 1, week 2, week 4, week 5, and week 6. The first 9 patients will receive a 100 microgram dose and the second 9 patients a 1 milligram dose of the peptide mixture.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HLA-A2 patients with histologically confirmed, TxN2-3M0 or metastatic breast cancer&#xD;
             with no evidence of disease who have completed their adjuvant systemic chemotherapy or&#xD;
             trastuzumab&#xD;
&#xD;
          -  Subjects will not be treated until 4 or more weeks after any prior chemotherapy,&#xD;
             radiation therapy or immunotherapy, but they may be receiving hormonal therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of autoimmune disease&#xD;
&#xD;
          -  Serious intercurrent chronic or acute illness&#xD;
&#xD;
          -  Active hepatitis&#xD;
&#xD;
          -  Serologic evidence for HIV, splenectomy&#xD;
&#xD;
          -  Receiving steroid or immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Morse, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kimberly Blackwell, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramila Philip, Ph.D.</last_name>
    <affiliation>Immunotope</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>May 5, 2008</study_first_submitted>
  <study_first_submitted_qc>May 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2008</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <responsible_party>
    <name_title>Ramila Philip, Ph.D.</name_title>
    <organization>Immunotope, Inc.</organization>
  </responsible_party>
  <keyword>Immunotherapeutic vaccine</keyword>
  <keyword>breast cancer</keyword>
  <keyword>TxN2-3M0 breast cancer</keyword>
  <keyword>metastatic breast cancer</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>antigen</keyword>
  <keyword>Histologically confirmed, TxN2-3M0 or metastatic breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

